Tevogen Bio Holdings Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Tevogen Bio is in severe financial distress with only $692k cash, $7.3M current liabilities, and a worsening stockholder deficit of -$9.8M. The company increased debt by $2M and continues burning cash with $5.4M quarterly losses while generating no revenue.
Red Flags Detected (6)
Cash position critically low at $692k vs $7.3M current liabilities
Stockholder deficit worsened from -$8.2M to -$9.8M in Q1 2026
Debt increased $2M to $6.4M under loan agreement
3 more red flags detected
Key Takeaways
Company faces imminent liquidity crisis with insufficient cash to cover current obligations
R&D spending remains high at $3.1M quarterly with no corresponding revenue
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.